Tags

Type your tag names separated by a space and hit enter

Solitary plasmacytoma.
Am J Clin Oncol. 2009 Dec; 32(6):612-7.AJ

Abstract

PURPOSE

To analyze the outcomes of patients treated for solitary plasmacytoma with definitive radiotherapy (RT).

MATERIAL AND METHODS

Thirty-two patients with solitary plasmacytoma of bone (SPB; 22 patients) and extramedullary plasmacytoma (EMP; 10 patients) were treated between 1963 and 2006. The median RT dose was around 42.7 Gy (range, 15-54 Gy) over a median of 25 fractions (range, 1-32 fractions). No patient received adjuvant chemotherapy. Median follow-up was 10.1 years (range, 1-33 years). Median follow-up on living patients was 7.3 years (range, 2.1-33 years).

RESULTS

The 10-year local-control rate after RT was 87%. All 4 patients who developed a local recurrence had SPBs > or = 5 cm. The 10-year multiple myeloma-free survival rates were: SPB, 30%; EMP, 90%; and overall, 50%. Progression to multiple myeloma occurred at a median of 25.1 months after RT. The 10-year overall and cause-specific survival rates were 65% and 77%, respectively. The 10-year cause-specific survival rate was 65% for patients with SPB versus 100% for those with EMP (P = 0.006).

CONCLUSION

Moderate dose RT results in a high rate of local control. Patients with SPB are more likely to progress to multiple myeloma, which adversely affects their survival compared with those with EMP.

Authors+Show Affiliations

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19593082

Citation

Dagan, Roi, et al. "Solitary Plasmacytoma." American Journal of Clinical Oncology, vol. 32, no. 6, 2009, pp. 612-7.
Dagan R, Morris CG, Kirwan J, et al. Solitary plasmacytoma. Am J Clin Oncol. 2009;32(6):612-7.
Dagan, R., Morris, C. G., Kirwan, J., & Mendenhall, W. M. (2009). Solitary plasmacytoma. American Journal of Clinical Oncology, 32(6), 612-7. https://doi.org/10.1097/COC.0b013e31819cca18
Dagan R, et al. Solitary Plasmacytoma. Am J Clin Oncol. 2009;32(6):612-7. PubMed PMID: 19593082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Solitary plasmacytoma. AU - Dagan,Roi, AU - Morris,Christopher G, AU - Kirwan,Jessica, AU - Mendenhall,William M, PY - 2009/7/14/entrez PY - 2009/7/14/pubmed PY - 2009/12/23/medline SP - 612 EP - 7 JF - American journal of clinical oncology JO - Am J Clin Oncol VL - 32 IS - 6 N2 - PURPOSE: To analyze the outcomes of patients treated for solitary plasmacytoma with definitive radiotherapy (RT). MATERIAL AND METHODS: Thirty-two patients with solitary plasmacytoma of bone (SPB; 22 patients) and extramedullary plasmacytoma (EMP; 10 patients) were treated between 1963 and 2006. The median RT dose was around 42.7 Gy (range, 15-54 Gy) over a median of 25 fractions (range, 1-32 fractions). No patient received adjuvant chemotherapy. Median follow-up was 10.1 years (range, 1-33 years). Median follow-up on living patients was 7.3 years (range, 2.1-33 years). RESULTS: The 10-year local-control rate after RT was 87%. All 4 patients who developed a local recurrence had SPBs > or = 5 cm. The 10-year multiple myeloma-free survival rates were: SPB, 30%; EMP, 90%; and overall, 50%. Progression to multiple myeloma occurred at a median of 25.1 months after RT. The 10-year overall and cause-specific survival rates were 65% and 77%, respectively. The 10-year cause-specific survival rate was 65% for patients with SPB versus 100% for those with EMP (P = 0.006). CONCLUSION: Moderate dose RT results in a high rate of local control. Patients with SPB are more likely to progress to multiple myeloma, which adversely affects their survival compared with those with EMP. SN - 1537-453X UR - https://www.unboundmedicine.com/medline/citation/19593082/Solitary_plasmacytoma_ L2 - https://doi.org/10.1097/COC.0b013e31819cca18 DB - PRIME DP - Unbound Medicine ER -